Novel antibody-antibiotic conjugate eliminates intracellular S. aureus

Area of Science:

• Microbiology
• Immunology
• Infectious Diseases

Background:

• Staphylococcus aureus is primarily viewed as an extracellular pathogen.
• Intracellular survival of S. aureus can create antibiotic-protected reservoirs, leading to persistent infections and treatment failures.
• Understanding intracellular bacterial reservoirs is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the role of intracellular Staphylococcus aureus as a reservoir for persistent infections.
• To develop and evaluate a novel therapeutic strategy targeting intracellular S. aureus.
• To assess the efficacy of the novel therapeutic compared to conventional antibiotics.

Main Methods:

• Confirmation of intracellular S. aureus reservoirs in a murine model.
• Development of an antibody-antibiotic conjugate (AAC) targeting S. aureus.
• Evaluation of AAC efficacy in treating S. aureus bacteremia in the presence of vancomycin.
• Assessment of bacterial survival within host cells.

Main Results:

• Intracellular S. aureus populations were confirmed as virulent reservoirs, capable of establishing infection even during vancomycin treatment.
• The developed antibody-antibiotic conjugate demonstrated significant efficacy in eliminating intracellular S. aureus.
• The AAC outperformed vancomycin in treating S. aureus bacteremia, highlighting its effectiveness against intracellular bacteria.
• Direct evidence was provided that intracellular S. aureus is a key factor in invasive infections.

Conclusions:

• Intracellular Staphylococcus aureus represents a significant, antibiotic-tolerant reservoir contributing to persistent infections.
• A novel antibody-antibiotic conjugate offers a promising therapeutic approach for eradicating intracellular S. aureus.
• Targeting intracellular bacterial reservoirs is essential for overcoming treatment failures in invasive S. aureus infections.